Target Name: PLAAT4
NCBI ID: G5920
Other Name(s): retinoid-inducible gene 1 protein | TIG3 | phospholipase A/acyltransferase-4 | Retinoic acid receptor responder protein 3 | phospholipase A and acyltransferase 4 | retinoic acid receptor responder 3 | RARRES3 | RIG1 | Tazarotene-induced gene 3 protein | RAR-responsive protein TIG3 | retinoic acid-inducible gene 1 | PLAAT-4; | HRSL4 | Retinoid-inducible gene 1 protein | PLA1/2-3 | HRASLS4 | retinoic acid receptor responder (tazarotene induced) 3 | Retinoic acid-inducible gene 1 | PLAT4_HUMAN | HRAS-like suppressor 4 | tazarotene-induced gene 3 protein | retinoic acid receptor responder protein 3 | Phospholipase A and acyltransferase 4 | PLAAT-4

PLAAT4: A Potential Drug Target for Various Diseases

PLAAT4 (Retinoid-Inducible Gene 1 Protein) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique function and structure make it an intriguing target for researchers to study and develop new treatments.

PLAAT4 is a transmembrane protein that is expressed in various tissues and cells throughout the body. It plays a crucial role in cell signaling and is involved in the regulation of signaling pathways that are important for both normal development and disease progression. One of its key functions is to regulate the levels of certain signaling molecules, including retinoids, in the body.

Retinoids are a type of signaling molecule that play a critical role in the development and maintenance of tissues and organs, including skin, hair, and nails. They are important for cell growth, differentiation, and repair, and are often used in the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. However, the levels of retinoids in the body can be difficult to regulate, and excessive levels can be harmful.

PLAAT4 plays a key role in regulating the levels of retinoids in the body by controlling the activity of a protein called RXR, which is a key regulator of the nuclear factor kappa B (NF-kappa-B) signaling pathway. The NF-kappa-B pathway is a complex network of proteins that are involved in the regulation of various cellular processes, including inflammation, cell growth, and differentiation.

Research has shown that PLAAT4 plays a critical role in the regulation of NF-kappa-B signaling by controlling the activity of RXR. This makes PLAAT4 an attractive target for drugs that are designed to inhibit the activity of RXR or its downstream targets. By doing so, these drugs can reduce the levels of retinoids in the body and potentially improve the health of various tissues and organs.

In addition to its role in regulating retinoid levels, PLAAT4 is also involved in the regulation of cellular signaling pathways that are important for normal development and disease progression. For example, PLAAT4 has been shown to be involved in the regulation of the Wnt signaling pathway, which is important for the development and maintenance of tissues and organs during embryonic development.

PLAAT4 is also involved in the regulation of the TGF-β signaling pathway, which is important for cell growth, differentiation, and repair. This makes PLAAT4 a potential target for drugs that are designed to inhibit the activity of TGF-β signaling pathway.

PLAAT4 is a transmembrane protein that is expressed in various tissues and cells throughout the body. Its unique function and structure make it an intriguing target for researchers to study and develop new treatments for various diseases. Its role in regulating retinoid levels and its involvement in cellular signaling pathways make PLAAT4 a potential drug target and biomarker for various diseases.

Protein Name: Phospholipase A And Acyltransferase 4

Functions: Exhibits both phospholipase A1/2 and acyltransferase activities (PubMed:19615464, PubMed:22605381, PubMed:22825852, PubMed:26503625). Shows phospholipase A1 (PLA1) and A2 (PLA2), catalyzing the calcium-independent release of fatty acids from the sn-1 or sn-2 position of glycerophospholipids (PubMed:19615464, PubMed:22605381, PubMed:22825852). For most substrates, PLA1 activity is much higher than PLA2 activity (PubMed:19615464). Shows O-acyltransferase activity, catalyzing the transfer of a fatty acyl group from glycerophospholipid to the hydroxyl group of lysophospholipid (PubMed:19615464). Shows N-acyltransferase activity, catalyzing the calcium-independent transfer of a fatty acyl group at the sn-1 position of phosphatidylcholine (PC) and other glycerophospholipids to the primary amine of phosphatidylethanolamine (PE), forming N-acylphosphatidylethanolamine (NAPE), which serves as precursor for N-acylethanolamines (NAEs) (PubMed:19615464, PubMed:22605381, PubMed:22825852). Promotes keratinocyte differentiation via activation of TGM1 (PubMed:17762858)

More Common Targets

PLAAT5 | PLAC1 | PLAC4 | PLAC8 | PLAC8L1 | PLAC9 | PLAC9P1 | PLAG1 | PLAGL1 | PLAGL2 | Plasma Membrane Calcium ATPase | PLAT | Platelet Glycoprotein Ib Complex | Platelet-activating factor acetylhydrolase isoform 1B complex | Platelet-Derived Growth Factor (PDGF) | Platelet-Derived Growth Factor Receptor | PLAU | PLAUR | PLB1 | PLBD1 | PLBD1-AS1 | PLBD2 | PLCB1 | PLCB2 | PLCB3 | PLCB4 | PLCD1 | PLCD3 | PLCD4 | PLCE1 | PLCE1-AS2 | PLCG1 | PLCG1-AS1 | PLCG2 | PLCH1 | PLCH2 | PLCL1 | PLCL2 | PLCXD1 | PLCXD2 | PLCXD3 | PLCZ1 | PLD1 | PLD2 | PLD3 | PLD4 | PLD5 | PLD6 | PLEC | PLEK | PLEK2 | PLEKHA1 | PLEKHA2 | PLEKHA3 | PLEKHA4 | PLEKHA5 | PLEKHA6 | PLEKHA7 | PLEKHA8 | PLEKHA8P1 | PLEKHB1 | PLEKHB2 | PLEKHD1 | PLEKHF1 | PLEKHF2 | PLEKHG1 | PLEKHG2 | PLEKHG3 | PLEKHG4 | PLEKHG4B | PLEKHG5 | PLEKHG6 | PLEKHG7 | PLEKHH1 | PLEKHH2 | PLEKHH3 | PLEKHJ1 | PLEKHM1 | PLEKHM1P1 | PLEKHM2 | PLEKHM3 | PLEKHN1 | PLEKHO1 | PLEKHO2 | PLEKHS1 | PLET1 | Plexin | PLG | PLGLA | PLGLB1 | PLGLB2 | PLGRKT | PLIN1 | PLIN2 | PLIN3 | PLIN4 | PLIN5 | PLK1 | PLK2 | PLK3